Cite
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
MLA
Jeong Han Kim, et al. “Hepatitis B Surface Antigen Levels at 6 Months after Treatment Can Predict the Efficacy of Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B.” Clinical and Molecular Hepatology, vol. 20, no. 3, Sept. 2014, pp. 274–82. EBSCOhost, https://doi.org/10.3350/cmh.2014.20.3.274.
APA
Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, & So Young Kwon. (2014). Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Clinical and Molecular Hepatology, 20(3), 274–282. https://doi.org/10.3350/cmh.2014.20.3.274
Chicago
Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, and So Young Kwon. 2014. “Hepatitis B Surface Antigen Levels at 6 Months after Treatment Can Predict the Efficacy of Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B.” Clinical and Molecular Hepatology 20 (3): 274–82. doi:10.3350/cmh.2014.20.3.274.